Canadian Cancer Trials Group (Queen's University)
Projects
-
Neoadjuvant precision therapy for non-small cell lung cancer: A platform for discovery
Tracking immunotherapy response to personalize treatment for lung cancer patients -
Canadian framework to improve predictive models for immunotherapy interventions (CAN-PREDICT-IT)
Developing multi-modal biomarkers to predict response to specific immunotherapies -
Improving patient matching to therapy via streamlining clinical trial eligibility criteria to guide precision oncology (PMATCH)
New software created by Marathon of Hope Cancer Centres Network researchers will connect cancer patients to clinical trials across the country
Related News
-
MOHCCN Pan-Canadian Projects underway with announcement of first grant recipients
In total, the Network will fund 20 such groups, representing a multi-million-dollar investment over the next three years that will contribute roughly 6,000 cases to the MOHCCN Gold Cohort, the largest... -
Marathon of Hope Cancer Centres Network and Canadian Cancer Trials Group partner on three pan-Canadian projects aimed at making immunotherapy more effective for cancer patients
A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams aiming to better understand ... -
PM2 CAN-IMPACT-IO a national immunotherapy biospecimen collection study has now opened
PM2 CAN-IMPACT-IO is a unique national initiative to measure, predict and assess cancer treatment outcomes in patients who have been treated with immunotherapy. Patients on CCTG clinical trials who co...
-
Regional Consortia
Princess Margaret Cancer Consortium
The Princess Margaret Cancer Consortium coalesces the expertise and efforts of clinicians, pathologists, software developers and data and translational scientists to help accelerate precision medicine...Read more
-
